Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Minocycline Bioequivalence Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01938508
Recruitment Status : Completed
First Posted : September 10, 2013
Last Update Posted : November 18, 2013
Sponsor:
Collaborator:
CECYC (Center of Scientific and Clinical Studies, CRO)
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
This study compared the bioavailability of two formulations 100 mg (one capsule or other respectively) of each one of the products, of Minocycline, under fasting conditions, in healthy Mexican volunteers of both sexes. The single dose study under fasting (10 hours prior to study) conditions, cross, with two treatments, two periods, two sequences (2x2) randomized sequence, balanced, and with a washout period of at least 7 days between each dose, in 24 healthy volunteers.

Condition or disease Intervention/treatment Phase
Skin Diseases Drug: Minocycline Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 28 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Bioequivalence Study Between Two Medications for the Oral Administration of 100 mg of Minocycline in Oral Solids in Healthy Volunteers.
Study Start Date : May 2013
Actual Primary Completion Date : June 2013
Actual Study Completion Date : June 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Skin Conditions

Arm Intervention/treatment
Experimental: Test
Minocycline 100 mg capsules Darier SA Dermatological Laboratories de CV (Micromycin ®).
Drug: Minocycline
minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline

Experimental: Reference
Minocycline 100 mg capsules (Micocin ®) Marketed and distributed by Triax Pharmaceuticals
Drug: Minocycline
minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline




Primary Outcome Measures :
  1. Bioavailability as assessed by composite of PK parameters. [ Time Frame: The samples were collected for each period to 0.0, 0.33, 0.66, 1.0, 1.33, 1.66, 2.0, 2.33, 2.66, 3.0, 4.0, 6.0, 8.0, 12.0, 16.0, 24.0, 36.0, 48.0 and 72.0 hours after administration ]
    The following pharmacokinetic (PK) parameters will assessed maximum observed concentration (Cmax), Area under the concentration time curve from time zero (pre-dose) to last common time of quantifiable concentration within a subject across all treatments (AUC0-t) and Area under the concentration time curve from time zero (pre-dose) extrapolated to infinite time (AUC0-inf).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Subjects aged between 18 and 55 years, of both genders.
  • Subjects who are in good health, based on the results of a complete medical history, valid for 6 months prior to baseline.
  • Subjects with laboratory studies, liver transaminases, hepatitis B test and C, HIV and Venereal Disease Research Laboratory (VDRL). These laboratory studies have been issued within 6 months prior to the start of this study.
  • Subjects who have 12-lead ECG no more than six months prior to baseline and this should be normal or normal physiologic variants.
  • Subjects that have a normal chest radiograph or physiologically normal anatomic variants.
  • Subjects with negative result in urine drug tests.
  • Subjects with negative test alcoholometry.
  • Female subjects with urine pregnancy test negative.
  • Subjects with a Body Mass Index (BMI) ranging from 19 to 26.5 kg/m2.
  • Subjects with laboratory results within the reference values or to +/- 10%. And if you have isolated abnormality above 10% is considered low clinical relevance criterion of Principal Investigator and indicate the relevance or otherwise of voluntary participation, as long as they ensure the safety of volunteers.
  • Subjects with vital signs diastolic pressure between 50 and 89 mmHg and between 90 and 139 mmHg for systolic, pulse rate between 55 and 100 beats per minute, respiratory rate of 12-24 breaths per minute and a temperature of 35.0 to 37.5 ° C.
  • Nonsmokers or smokers who have not smoked at least 10 hours before the start of the study.
  • Without alcohol intake for 48 hours prior to study drug administration.
  • Subjects signed informed consent, having informed the potential risks and benefits of participation, and their willingness and availability to participate in the full study, may leave the study at the time they so choose.
  • Female participants must not be pregnant or breast-feeding, plus those who are sexually active should have a method of birth control to prevent pregnancy during the investigation considered the following secure methods (Male condom combined with a vaginal spermicide (Foam, gel, film, cream, or suppository, combined with a male condom female diaphragm, either with or without a vaginal spermicide, intrauterine device and also provide you with a list of other contraceptive methods in order that you do not become pregnant during the investigation).
  • Prior to joining the first period sign a commitment letter no pregnancy.

Exclusion Criteria:

  • Subjects with a history of hypersensitivity to the study drug or any other drugs belonging to the group of study drug.
  • Subjects with a history of cardiovascular disease, renal, hepatic, metabolic, gastrointestinal, neurological, endocrine, hematopoietic, psychiatric or other organic abnormalities.
  • Subjects requiring any other medications that interfere with the quantification and / or kinetic study drug.
  • Subjects exposed to agents known as inducers or inhibitors of hepatic enzyme systems.
  • Subjects who had taken potentially toxic drugs within 30 days before the start of the study.
  • Subjects who have taken any drug within 14 days or 7 half-lives before the start of the study.
  • Subjects who were hospitalized for any reason or were seriously ill within 60 days before the study.
  • Subjects who have received an investigational drug within 60 days before the start of the study.
  • Subjects who have donated or lost 450 mL or more of blood within 45 days prior to baseline.
  • Subjects with a recent history of drug abuse, including alcohol.
  • Female subjects with a positive pregnancy test in urine.
  • Subjects who consumed food or beverages that interact pharmacologically with the study drug (particularly those that are known sources of xanthines: caffeine, cola drinks, theobromine, and theophylline in the 10 hours before the test.
  • Subjects with grapefruit juice consumption in the 10 hours before the test.
  • Subjects with inability to understand or unwilling to sign the consent form.
  • Subjects who are discharged from the database by COFEPRIS are participating in another study of bioequivalence.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01938508


Locations
Layout table for location information
Mexico
GSK Investigational Site
Mexico City, Mexico, 03100
Sponsors and Collaborators
GlaxoSmithKline
CECYC (Center of Scientific and Clinical Studies, CRO)
Investigators
Layout table for investigator information
Study Director: GSK Clinical Trials GlaxoSmithKline

Layout table for additonal information
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01938508     History of Changes
Other Study ID Numbers: 200611
First Posted: September 10, 2013    Key Record Dates
Last Update Posted: November 18, 2013
Last Verified: November 2013

Keywords provided by GlaxoSmithKline:
dermatitis
Minocycline
bioavailability

Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases
Minocycline
Anti-Bacterial Agents
Anti-Infective Agents